Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors

Preclinical studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clinically evaluated vascular-disrupting agents.

Ankle arthrodesis versus total ankle replacement: how do I decide?

Taking into account numerous individual criteria, the correct indication substantially influences the outcome of patients with end-stage ankle arthritis treated by ankle arthrodesis or total ankle replacement. The purpose of this report is to assist the foot and ankle surgeon or orthopedic surgeon involved in choosing ankle arthrodesis or total ankle replacement in decision-making. Balancing the criteria that are discussed in consideration of the recent relevant literature and evidence available, the surgeon is directed to the correct individual decision.

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer

The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent. Preclinical models have shown that the addition of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly increases antitumor activity.